Marcum Wealth LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Marcum Wealth LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 5.2% in the fourth quarter, HoldingsChannel reports. The firm owned 1,386 shares of the company’s stock after buying an additional 69 shares during the quarter. Marcum Wealth LLC’s holdings in Zoetis were worth $226,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. State Street Corp increased its holdings in Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after purchasing an additional 95,856 shares during the period. Geode Capital Management LLC grew its position in shares of Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after buying an additional 185,364 shares in the last quarter. Mizuho Securities USA LLC increased its stake in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after buying an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after acquiring an additional 194,542 shares during the last quarter. Finally, Clearbridge Investments LLC grew its holdings in Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after acquiring an additional 166,517 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Finally, Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Trading Up 1.7 %

Shares of Zoetis stock opened at $167.23 on Thursday. The company’s fifty day moving average is $171.31 and its two-hundred day moving average is $180.16. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a market capitalization of $75.45 billion, a P/E ratio of 31.43, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.